Business Context and Reporting Period
This Form 8-K was filed by Spero Therapeutics, Inc. on February 11, 2020. The filing primarily addresses the commencement of a rights offering to stockholders and provides a preliminary estimate of the company's cash balance as of December 31, 2019. The company is an emerging growth company focused on developing novel antibiotics.
Key Financial Metrics
- Cash Position: Preliminary estimate of cash, cash equivalents, and marketable securities as of December 31, 2019, was approximately $82.0 million.
- Committed Funding: Total committed funding under the BARDA award to date is $34.1 million, including a recently exercised option for $15.9 million. A second option for $12.6 million remains available subject to milestones. The DTRA provides up to $10.0 million for nonclinical biodefense aspects.
- Liquidity and Runway: Existing cash and committed non-dilutive funding are expected to fund operations into the fourth quarter of 2020. With net proceeds from the rights offering, the company expects to fund operations into the first quarter of 2021.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or margin figures for the period.
Material Changes and Recent Developments
- Going Concern Status: The company has determined there is substantial doubt regarding its ability to continue as a going concern because funds on hand and expected proceeds will not be sufficient to fund operations for more than one year beyond the filing date. An explanatory paragraph regarding this doubt is expected in the independent auditor's opinion on the 2019 Form 10-K.
- Tebipenem HBr: An independent data review committee recommended continuing the pivotal Phase 3 ADAPT-PO trial without dose modification. BARDA exercised a contract option providing $15.9 million for manufacturing and development activities.
- SPR720: Phase 1 data indicated the drug is well-tolerated with a pharmacokinetic profile supporting advancement to a Phase 2a trial in the second half of 2020.
- Potentiator Platform: SPR206 was selected as the lead product candidate based on Phase 1 safety and tolerability data. Development of SPR741 was discontinued effective January 1, 2020, and the license agreement with Northern Antibiotics Oy was terminated.
Guidance, Outlook, and Risks
- Outlook: Top-line data for the tebipenem HBr Phase 3 trial is expected in the third quarter of 2020. The company plans to file an NDA for tebipenem HBr in the first quarter of 2021, contingent on successful funding.
- Risks: The company requires additional funding to reach regulatory approval and commercialization. There is no assurance that sufficient funding will be obtained on acceptable terms. Failure to secure funding could force delays or elimination of research and development programs.
- Unusual Items: The filing includes a rights offering to raise capital. The preliminary financial data is unaudited and subject to change upon completion of the 2019 financial statements.
Investor Verification Checklist
- Verify the final audited cash balance and liquidity position in the upcoming Form 10-K for the year ended December 31, 2019.
- Confirm the closing status and net proceeds of the rights offering announced on February 11, 2020.
- Monitor the timeline for the top-line data readout of the tebipenem HBr Phase 3 trial (expected Q3 2020).
- Review the specific terms and milestones required to exercise the remaining $12.6 million BARDA funding option.
- Assess the impact of the discontinued SPR741 program on the company's overall pipeline strategy.